Market closed
IGM Biosciences/$IGMS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About IGM Biosciences
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Ticker
$IGMS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
198
Website
IGM Biosciences Metrics
BasicAdvanced
$80M
-
-$3.65
0.01
-
Price and volume
Market cap
$80M
Beta
0.01
52-week high
$17.13
52-week low
$1.26
Average daily volume
714K
Financial strength
Current ratio
5.223
Quick ratio
4.999
Long term debt to equity
49.605
Total debt to equity
58.086
Management effectiveness
Return on assets (TTM)
-37.38%
Return on equity (TTM)
-132.11%
Valuation
Price to revenue (TTM)
27.682
Price to book
1.01
Price to tangible book (TTM)
1.01
Price to free cash flow (TTM)
-0.468
Growth
Revenue change (TTM)
57.64%
Earnings per share change (TTM)
-25.92%
3-year earnings per share growth (CAGR)
-4.86%
What the Analysts think about IGM Biosciences
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for IGM Biosciences stock.
IGM Biosciences Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
IGM Biosciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
IGM Biosciences News
AllArticlesVideos
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
Accesswire·4 weeks ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
Accesswire·1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for IGM Biosciences stock?
IGM Biosciences (IGMS) has a market cap of $80M as of February 26, 2025.
What is the P/E ratio for IGM Biosciences stock?
The price to earnings (P/E) ratio for IGM Biosciences (IGMS) stock is 0 as of February 26, 2025.
Does IGM Biosciences stock pay dividends?
No, IGM Biosciences (IGMS) stock does not pay dividends to its shareholders as of February 26, 2025.
When is the next IGM Biosciences dividend payment date?
IGM Biosciences (IGMS) stock does not pay dividends to its shareholders.
What is the beta indicator for IGM Biosciences?
IGM Biosciences (IGMS) has a beta rating of 0.01. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.